Complete DTIL Stock Valuation Analysis
Comprehensive intrinsic value analysis using 2 different methodologies
DTIL DCF Analysis
DTIL (Precision BioSciences, Inc.) discounted cash flow analysis with multiple scenarios, growth assumptions, and terminal value calculations
Financial Projections
| Metrics | 2022 (Historical) | 2023 (Historical) | 2024 (Historical) | 2025 (Projected) | 2026 (Projected) | 2027 (Projected) | 2028 (Projected) | 2029 (Projected) |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.1M | $48.7M | $68.7M | $85.9M | $107.3M | $134.2M | $167.7M | $209.6M |
| Revenue Growth % | - | 94.1% | 41.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| EBIT | $-100.4M | $-43.7M | $-26.2M | $4.3M | $5.4M | $6.7M | $8.4M | $10.5M |
| EBIT Margin % | -399.9% | -89.8% | -38.1% | 5.0% | 5.0% | 5.0% | 5.0% | 5.0% |
| Tax Rate % | 25.0% | 25.0% | 0.0% | 20.0% | 20.5% | 21.0% | 21.5% | 22.0% |
| NOPAT | $-75.3M | $-32.8M | $-26.2M | $3.4M | $4.3M | $5.3M | $6.6M | $8.2M |
| NOPAT Margin % | -299.9% | -67.3% | -38.1% | 4.0% | 4.0% | 4.0% | 3.9% | 3.9% |
| Capex | $3.3M | $2.3M | $250.0K | $5.0M | $5.9M | $7.0M | $8.4M | $9.9M |
| Capex / Revenue % | 13.2% | 4.7% | 0.4% | 5.8% | 5.5% | 5.3% | 5.0% | 4.7% |
| Depreciation | $9.0M | $8.3M | $4.6M | $17.0M | $21.3M | $26.6M | $33.3M | $41.6M |
| D&A / Revenue % | 35.9% | 16.9% | 6.7% | 19.8% | 19.8% | 19.8% | 19.8% | 19.8% |
| Change in NWC | $13.7M | $-53.1M | $-6.4M | $-4.0M | $-4.0M | $-4.0M | $-4.0M | $-4.0M |
| NWC Change / Revenue % | 54.5% | -108.9% | -9.3% | -4.6% | -3.7% | -3.0% | -2.4% | -1.9% |
| Unlevered FCF | $-83.3M | $26.2M | $-15.5M | $19.4M | $23.6M | $28.8M | $35.4M | $43.8M |
| UFCF % Chg. | - | 131.5% | -159.0% | 225.6% | 21.4% | 22.2% | 22.9% | 23.5% |
| FCF / Revenue % | -331.7% | 53.9% | -22.5% | 22.6% | 22.0% | 21.5% | 21.1% | 20.9% |
| Discount Factor | - | - | - | 0.918 | 0.842 | 0.772 | 0.709 | 0.650 |
| Present Value of FCF | - | - | - | $17.8M | $19.9M | $22.3M | $25.1M | $28.5M |
| Sum of PV of UFCF | - | - | - | $17.8M | $37.7M | $60.0M | $85.1M | $113.6M |
WACC Calculation
Weighted Average Cost of Capital used for discounting cash flows.
| WACC Calculation | Value |
|---|---|
| Cost of Debt | 6.9% |
| Tax Rate | 20.0% |
| After Tax Cost of Debt | 5.5% |
| Risk Free Rate | 4.40% |
| Market Risk Premium | 4.3% |
| Beta | 1.47 |
| Cost of Equity | 10.8% |
| Total Debt | $30.0M |
| Market Cap | $58.9M |
| Total Capital | $88.9M |
| Debt Weighting | 33.8% |
| Equity Weighting | 66.2% |
| WACC | 9.0% |
Terminal Value
Choose between perpetuity growth or exit multiple methods.
| Terminal Value Calculation | Value |
|---|---|
| Terminal Growth Rate | 2.5% |
| Final Year FCF | $43.8M |
| Terminal Value | $691.7M |
| PV of Terminal Value | $449.8M |
| Cumulative PV of UFCF | $113.6M |
| Net Debt | $-55.9M |
| Equity Value | $619.2M |
| Shares Outstanding | 6.9M |
| Implied Share Price | $90 |
| Current Share Price | $5 |
| Implied Upside/(Downside) | +1593.9% |
Valuation Summary
$89.95
Implied Price
$5.31
Current Price
+1593.9%
Upside/Downside
9.0%
WACC
DTIL Peer Valuation Analysis
Relative valuation based on comparable company trading multiples
Peer Valuation Analysis
Fair Value Range Analysis
Based on median multiples from 9 peer companies in Healthcare
P/E Ratio
$-0.10
-101.8%
Peer Median: 0.0x
EV/EBITDA
$0.00
-100.0%
Peer Median: 0.1x
P/S Ratio
$5.31
+0.0%
Peer Median: 1.2x
Interpretation: Each multiple provides a different perspective on fair value. Consider which multiple is most relevant for DTIL's business model and current situation.
Multiple Comparison
| Multiple | DTIL Current | Peer Median | Peer Average | Premium/Discount | Assessment |
|---|---|---|---|---|---|
| P/E Ratio | -2.2x | 0.0x | 0.0x | -5507.0% | Undervalued |
| EV/EBITDA | Infinityx | 0.1x | 0.1x | Infinity% | Overvalued |
| P/S Ratio | 1.2x | 1.2x | 1.2x | 0.0% | Fair Value |
Peer Companies
Click any company to view their valuation
| Company | Market Cap | P/E Ratio | EV/EBITDA | P/S Ratio |
|---|---|---|---|---|
| $0.06B | 0.0x | 0.1x | 0.0x | |
| $0.05B | 0.0x | 0.0x | 2.8x | |
| $0.05B | 0.0x | 0.0x | 296.7x | |
| $0.06B | 0.0x | 0.0x | 0.0x | |
| $0.05B | 0.0x | 0.0x | 195.3x | |
| $0.06B | 0.0x | 0.0x | 1.2x | |
| $0.06B | 0.0x | 0.0x | 1.0x | |
| $0.06B | 0.0x | 0.0x | 48.9x | |
| $0.09B | 0.0x | 0.0x | 77.0x |